{
  "ticker": "LLY",
  "target_date": "2025-06-02",
  "actual_date": "2025-06-02",
  "collected_at": "2025-12-08T11:50:19.433100",
  "price": {
    "open": 729.82,
    "high": 744.64,
    "low": 728.03,
    "close": 744.3893432617188,
    "volume": 2946900,
    "change_1d_pct": 1.28,
    "change_7d_pct": 3.06,
    "change_30d_pct": -10.87
  },
  "technicals": {
    "rsi_14": 47.99,
    "sma_20": 740.34,
    "sma_50": 778.26,
    "macd": -18.301,
    "macd_signal": -20.404,
    "macd_histogram": 2.103,
    "bb_upper": 791.97,
    "bb_lower": 688.72,
    "price_vs_sma20_pct": 0.55,
    "price_vs_sma50_pct": -4.35,
    "volume_ratio": 0.64
  },
  "fundamentals": {
    "market_cap": 891790688256,
    "pe_ratio": 48.740566,
    "forward_pe": 43.900925,
    "price_to_book": 37.45463,
    "price_to_sales": 15.008308,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.54,
    "pct_from_52w_low": 59.48
  },
  "macro": {
    "spy": {
      "price": 589.33,
      "change_1d_pct": 0.56,
      "change_7d_pct": 1.65
    },
    "vix": {
      "level": 18.36,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.46
    },
    "dollar_index": {
      "level": 98.7
    },
    "gold": {
      "price": 3370.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "GARP: Growth ETF With A Solid Track Record",
      "source": "SeekingAlpha",
      "datetime": 1748884827,
      "summary": "iShares MSCI USA Quality GARP ETF holds 135 growth stocks weighted based on value and quality. Read the full ETF analysis and more like it here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=effd3783a0b241fa2ff614b4a6737f5f25dd55a40fa870fdf54248400d4f340f"
    },
    {
      "headline": "Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference",
      "source": "Yahoo",
      "datetime": 1748872800,
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=d793d985ac6a84767ce1bd1a5f3dbdaa1cd86ce9ff2848313c822f5eec96cbdd"
    },
    {
      "headline": "Lilly presents first clinical data for its investigational, next-generation FR\u03b1 targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting",
      "source": "Yahoo",
      "datetime": 1748865600,
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FR\u03b1) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FR\u03b1 expression levels in women with heavily pre-treated platinu",
      "url": "https://finnhub.io/api/news?id=21ac380e96dc234eba5fcac9617872a9ebbd92f55dbca59bd88e2ff3cf41d879"
    },
    {
      "headline": "Weight Loss Drug ETF (THNR) Hits New 52-Week High",
      "source": "Yahoo",
      "datetime": 1748862720,
      "summary": "THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?",
      "url": "https://finnhub.io/api/news?id=7c1cf7e380603cc6cd95fe0e6a316d6ad89ade8f83831e533fa67e3eab048a41"
    },
    {
      "headline": "Could Viking Therapeutics Become the Next Eli Lilly?",
      "source": "Yahoo",
      "datetime": 1748861100,
      "summary": "Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications.  Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete with Eli Lilly's Zepbound.  The obesity treatment market is booming, with groundbreaking drugs like",
      "url": "https://finnhub.io/api/news?id=bcbd055db916afc0c680f44a5685a2c6bad5b78abcbdd48b40c9d03a2f8e4c41"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-27",
      "description": "xslF345X05/wk-form4_1748376794.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000156/xslF345X05/wk-form4_1748376794.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772733.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000154/xslF345X05/wk-form4_1747772733.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772668.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000152/xslF345X05/wk-form4_1747772668.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772589.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000150/xslF345X05/wk-form4_1747772589.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772518.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000148/xslF345X05/wk-form4_1747772518.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}